Vestmark Advisory Solutions Inc. Takes Position in UiPath Inc. (NYSE:PATH)

Vestmark Advisory Solutions Inc. acquired a new position in shares of UiPath Inc. (NYSE:PATH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 625,740 shares of the healthcare company’s stock, valued at approximately $15,543,000. UiPath comprises approximately 0.8% of Vestmark Advisory Solutions Inc.’s portfolio, making the stock its 27th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. M&T Bank Corp raised its holdings in UiPath by 35.8% during the 4th quarter. M&T Bank Corp now owns 20,861 shares of the healthcare company’s stock worth $519,000 after purchasing an additional 5,495 shares during the last quarter. Amalgamated Bank raised its stake in UiPath by 8.3% during the fourth quarter. Amalgamated Bank now owns 82,148 shares of the healthcare company’s stock worth $2,041,000 after buying an additional 6,303 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in UiPath by 53.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,096,647 shares of the healthcare company’s stock valued at $27,241,000 after buying an additional 380,959 shares during the period. Swiss National Bank boosted its position in UiPath by 4.9% during the fourth quarter. Swiss National Bank now owns 1,211,500 shares of the healthcare company’s stock valued at $30,094,000 after acquiring an additional 56,600 shares during the last quarter. Finally, JFG Wealth Management LLC acquired a new stake in UiPath during the 4th quarter worth about $373,000. 62.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on PATH. Truist Financial restated a “buy” rating and set a $32.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Scotiabank increased their target price on UiPath from $29.00 to $30.00 and gave the stock a “sector perform” rating in a report on Thursday, March 14th. JPMorgan Chase & Co. raised shares of UiPath from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Mizuho raised their price objective on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Thursday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.41.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now owns 87,505 shares of the company’s stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 72,000 shares of company stock worth $1,591,360 over the last ninety days. 31.03% of the stock is owned by corporate insiders.

UiPath Trading Up 0.9 %

Shares of PATH stock traded up $0.18 during trading hours on Friday, reaching $19.48. The stock had a trading volume of 3,862,423 shares, compared to its average volume of 5,757,008. The stock’s fifty day simple moving average is $21.75 and its 200 day simple moving average is $21.65. The firm has a market capitalization of $11.08 billion, a PE ratio of -114.58 and a beta of 1.01. UiPath Inc. has a 12 month low of $12.38 and a 12 month high of $27.87.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $405.25 million during the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. As a group, equities research analysts anticipate that UiPath Inc. will post -0.04 EPS for the current fiscal year.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.